Cargando…

Disitamab Vedotin plus anti-PD-1 antibody show good efficacy in refractory primary urethral cancer with low HER2 expression: a case report

Primary urethral carcinoma (PUC) has a low incidence, but with high aggressiveness. Most of the patients are found in late stage, with poor prognosis. At present, chemotherapy is still the main treatment for metastatic PUC, but it has limited effect. Here, we report a case of metastatic PUC with low...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Yue, Xue, Yin-Yin, Zhao, Ya-Qin, Chen, Ye, Li, Zhi-Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601644/
https://www.ncbi.nlm.nih.gov/pubmed/37901233
http://dx.doi.org/10.3389/fimmu.2023.1254812
_version_ 1785126237862100992
author Zheng, Yue
Xue, Yin-Yin
Zhao, Ya-Qin
Chen, Ye
Li, Zhi-Ping
author_facet Zheng, Yue
Xue, Yin-Yin
Zhao, Ya-Qin
Chen, Ye
Li, Zhi-Ping
author_sort Zheng, Yue
collection PubMed
description Primary urethral carcinoma (PUC) has a low incidence, but with high aggressiveness. Most of the patients are found in late stage, with poor prognosis. At present, chemotherapy is still the main treatment for metastatic PUC, but it has limited effect. Here, we report a case of metastatic PUC with low HER2 expression that developed disease progression after multiline therapy including chemotherapy, programmed death-1 (PD-1) inhibitors and multi-targeted receptor tyrosine kinase (RTK) inhibitor. After receiving Disitamab Vedotin(a novel antibody drug conjugate, ADC) and toripalimab (a PD-1 inhibitor), the patient achieved persistent PR, and the PFS exceeded 12 months up to now. Our report indicates that, despite the patient of metastatic PUC has low expression of HER2, it is still possible to benefit from Disitamab Vedotin combined with PD-1 inhibitor, which may reverse the drug resistance of PD-1 inhibitor and chemotherapy to a certain extent. But larger sample studies are needed to determine the efficacy of this treatment strategy and its impact on survival.
format Online
Article
Text
id pubmed-10601644
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-106016442023-10-27 Disitamab Vedotin plus anti-PD-1 antibody show good efficacy in refractory primary urethral cancer with low HER2 expression: a case report Zheng, Yue Xue, Yin-Yin Zhao, Ya-Qin Chen, Ye Li, Zhi-Ping Front Immunol Immunology Primary urethral carcinoma (PUC) has a low incidence, but with high aggressiveness. Most of the patients are found in late stage, with poor prognosis. At present, chemotherapy is still the main treatment for metastatic PUC, but it has limited effect. Here, we report a case of metastatic PUC with low HER2 expression that developed disease progression after multiline therapy including chemotherapy, programmed death-1 (PD-1) inhibitors and multi-targeted receptor tyrosine kinase (RTK) inhibitor. After receiving Disitamab Vedotin(a novel antibody drug conjugate, ADC) and toripalimab (a PD-1 inhibitor), the patient achieved persistent PR, and the PFS exceeded 12 months up to now. Our report indicates that, despite the patient of metastatic PUC has low expression of HER2, it is still possible to benefit from Disitamab Vedotin combined with PD-1 inhibitor, which may reverse the drug resistance of PD-1 inhibitor and chemotherapy to a certain extent. But larger sample studies are needed to determine the efficacy of this treatment strategy and its impact on survival. Frontiers Media S.A. 2023-10-12 /pmc/articles/PMC10601644/ /pubmed/37901233 http://dx.doi.org/10.3389/fimmu.2023.1254812 Text en Copyright © 2023 Zheng, Xue, Zhao, Chen and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Zheng, Yue
Xue, Yin-Yin
Zhao, Ya-Qin
Chen, Ye
Li, Zhi-Ping
Disitamab Vedotin plus anti-PD-1 antibody show good efficacy in refractory primary urethral cancer with low HER2 expression: a case report
title Disitamab Vedotin plus anti-PD-1 antibody show good efficacy in refractory primary urethral cancer with low HER2 expression: a case report
title_full Disitamab Vedotin plus anti-PD-1 antibody show good efficacy in refractory primary urethral cancer with low HER2 expression: a case report
title_fullStr Disitamab Vedotin plus anti-PD-1 antibody show good efficacy in refractory primary urethral cancer with low HER2 expression: a case report
title_full_unstemmed Disitamab Vedotin plus anti-PD-1 antibody show good efficacy in refractory primary urethral cancer with low HER2 expression: a case report
title_short Disitamab Vedotin plus anti-PD-1 antibody show good efficacy in refractory primary urethral cancer with low HER2 expression: a case report
title_sort disitamab vedotin plus anti-pd-1 antibody show good efficacy in refractory primary urethral cancer with low her2 expression: a case report
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601644/
https://www.ncbi.nlm.nih.gov/pubmed/37901233
http://dx.doi.org/10.3389/fimmu.2023.1254812
work_keys_str_mv AT zhengyue disitamabvedotinplusantipd1antibodyshowgoodefficacyinrefractoryprimaryurethralcancerwithlowher2expressionacasereport
AT xueyinyin disitamabvedotinplusantipd1antibodyshowgoodefficacyinrefractoryprimaryurethralcancerwithlowher2expressionacasereport
AT zhaoyaqin disitamabvedotinplusantipd1antibodyshowgoodefficacyinrefractoryprimaryurethralcancerwithlowher2expressionacasereport
AT chenye disitamabvedotinplusantipd1antibodyshowgoodefficacyinrefractoryprimaryurethralcancerwithlowher2expressionacasereport
AT lizhiping disitamabvedotinplusantipd1antibodyshowgoodefficacyinrefractoryprimaryurethralcancerwithlowher2expressionacasereport